Compare Synopsys, Inc. (SNPS) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Tilray Brands Inc — how do they compare? Synopsys, Inc. trades at $503.66 (market cap $95.39B), while Tilray Brands Inc trades at $3.6 (market cap $530.54M). The key difference: Synopsys, Inc. is far larger — about 179.8× Tilray Brands Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and Tilray Brands Inc for 31 Days on average.
| SNPS | TLRY | |
|---|---|---|
Market Cap | $95.39B | $530.54M |
Volume | 3,374,903 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $534.56 | $21.00 |
52-Week Low | $367.70 | $3.57 |
Typical Hold Time | 71 Days | 31 Days |
Enterprise Value | $102.62B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, but maintains strong bullish momentum with recent AI-driven partnerships and earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5%, supported by a 72.38% gross margin. Technical indicators show bullish moving averages but overbought RSI levels above 89, with key support at $500 and resistance at $505. Recent announcements with OpenAI and Amazon have driven significant investor optimism and price target upgrades.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus target suggesting 14% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks include high valuation (P/E 87.7) and execution challenges in large-scale partnerships. The stock's proximity to all-time highs requires careful monitoring of earnings delivery and competitive pressures in the EDA market.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
